On September 10th I mentioned NeoPharm as a good long-term bio-tech stock to get into. After a voluntary delisting from Nasdaq earlier this year NEOL has climbed from 0.07 in February to it's current price at 0.39 on the OTC BB.
Neopharm has 5 drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer, interstitial pulmonary fibrosis and asthma. The company has cash on hand to fund anticipated development activities into the second quarter of 2010.
Below is a link from an article on NeoPharm from OneMedPlace.
NeoPharm: A Pipeline with Multiple Catalysts
I don't know what the future holds for NEOL but if you invest in enough companies like this your patience should be rewarded. Buy low, sell high and be patient, my man.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment